Brokers Issue Forecasts for BCAX FY2026 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Stock analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of Bicara Therapeutics in a research note issued to investors on Wednesday, November 11th. HC Wainwright analyst R. Burns forecasts that the company will post earnings per share of ($3.86) for the year. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($3.82) per share. HC Wainwright also issued estimates for Bicara Therapeutics’ Q4 2026 earnings at ($1.07) EPS.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, November 9th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.22).

Several other brokerages have also recently commented on BCAX. The Goldman Sachs Group cut shares of Bicara Therapeutics from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $20.00 to $8.00 in a research report on Friday, October 30th. HSBC lowered shares of Bicara Therapeutics to an “equal weight” rating in a research report on Tuesday, September 22nd. BTIG Research lowered their price objective on shares of Bicara Therapeutics from $39.00 to $37.00 and set a “buy” rating on the stock in a research note on Tuesday. Morgan Stanley dropped their target price on shares of Bicara Therapeutics from $41.00 to $30.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a report on Thursday, September 10th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $30.33.

Bicara Therapeutics Stock Down 4.0%

Shares of BCAX stock opened at $10.11 on Friday. The stock has a 50-day simple moving average of $17.10 and a 200 day simple moving average of $20.81. Bicara Therapeutics has a fifty-two week low of $7.87 and a fifty-two week high of $30.99. The stock has a market capitalization of $671.20 million, a P/E ratio of -2.91 and a beta of -0.33.

Insider Buying and Selling at Bicara Therapeutics

In other news, CEO Ryan Cohlhepp sold 17,500 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total transaction of $400,750.00. Following the completion of the sale, the chief executive officer directly owned 181,641 shares of the company’s stock, valued at $4,159,578.90. This trade represents a 8.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of BCAX. BlackRock Inc. purchased a new stake in shares of Bicara Therapeutics during the second quarter valued at $114,250,000. Jupiter Topco LLC acquired a new position in shares of Bicara Therapeutics in the 2nd quarter valued at $93,957,000. Janus Henderson Group PLC boosted its position in shares of Bicara Therapeutics by 26.2% in the 1st quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock valued at $66,350,000 after purchasing an additional 692,933 shares during the period. Siren L.L.C. increased its stake in Bicara Therapeutics by 11.2% in the 1st quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock worth $115,421,000 after purchasing an additional 586,001 shares in the last quarter. Finally, Palo Alto Investors LP purchased a new position in Bicara Therapeutics in the 2nd quarter worth about $16,341,614.

Key Headlines Impacting Bicara Therapeutics

These are some of the BCAX headlines that stood out recently:

• Positive Sentiment: HC Wainwright kept its Buy rating on BCAX and a $36 price target, which could support investor optimism despite the target reduction from $42. HC Wainwright target update
• Negative Sentiment: Stifel Nicolaus and Morgan Stanley reportedly cut their BCAX price targets, and BTIG Research issued a pessimistic forecast. These actions may weigh on sentiment; the provided headlines do not specify the revised targets or detailed rationale. Stifel target cut Morgan Stanley target cut BTIG forecast
• Negative Sentiment: HC Wainwright’s 2027 estimates project continuing quarterly losses, including a full-year loss of $4.63 per share. Expectations of ongoing losses can be a headwind for a clinical-stage biotech, even with the firm’s Buy rating.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.